Swati Agarwal-Sinha, MD
Ophthalmology · Green Bay, WINPI 1659578623
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AbbVie at 50.9% of the total. Reporting peaked in 2024 at $2,216 and has fallen 88.9% since, to $246 in 2025. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $250.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Natus Medical Incorporated$500
- Genentech USA, Inc.$444
- Genentech, Inc.$287
- Dutch Ophthalmic, USA$211
- Carl Zeiss Meditec, Inc.$206
- plus $323 from 3 others
Across 24 payments — averaging $4910.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$114K
- Travere Therapeutics, Inc.$3K
What the payments were for
- Consulting fees$2,00050%
- Speaking & faculty fees$50012%
- Food & beverage$1,51638%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 2 | $2,045 |
| Natus Medical Incorporated | 1 | $500 |
| Genentech USA, Inc. | 4 | $444 |
| Genentech, Inc. | 2 | $287 |
| Dutch Ophthalmic, USA | 2 | $211 |
| Carl Zeiss Meditec, Inc. | 1 | $206 |
| Regeneron Healthcare Solutions, Inc. | 1 | $120 |
| Regeneron | 2 | $118 |
| Spark Therapeutics, Inc. | 1 | $86 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$2,000
- VABYSMO$434
- SUSVIMO$419
- Lucentis$293
- Clarus 700$206
- EVA, combined machine$142
- EYLEA HD$120
How this compares
$4,016 in reported general payments places this provider in the 90th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 56 | $3,112 |
| Ketorolac Tromethamine | 21 | $1,053 |
| Ofloxacin | 34 | $446 |
| Latanoprost | 14 | $202 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $139 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Green Bay
- Alexander FosterGreen Bay$3K
- Kevin WienkersGreen Bay$3K
- Tyson SchwiesowGreen Bay$3K
- Matthew ThompsonGreen Bay$3K
- Inder SinghRacine$2.5M
- Deepak SambharaWausau$388K
- John VukichWauwatosa$356K
- Eugene EldridgeKenosha$294K
- Michael ShapiroMadison$71K
- Douglas SalmAppleton$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.